# Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC

> **NCT00544453** · PHASE1 · TERMINATED · sponsor: **Molecular NeuroImaging** · enrollment: 2 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [123I] MNI-308

## Key facts

- **NCT ID:** NCT00544453
- **Lead sponsor:** Molecular NeuroImaging
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2007-10
- **Final completion:** 2008-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Preliminary data showed \[123I\] MNI-308 not a useful tool in detection of AD.
- **Last updated:** 2009-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544453, "Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00544453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*